Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052891 | 0.87 | LOXL2 (0.56) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL3047572 | 0.87 | LOXL2 (0.56) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL3052274 | 0.77 | LOXL2 (0.40) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL3049889 | 0.76 | LOXL2 (0.39) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL31065503 | 0.75 | LOXL2 (0.62) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL11865173 | 0.73 | LOXL2 (0.68) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL3039103 | 0.73 | HTR2A (0.52) | RAB9ASMN1; SMN2PCSK9MAPTNR3C1 | |
| SCHEMBL11163173 | 0.70 | LOXL2 (0.68) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL865051 | 0.69 | LOXL2 (0.72) | LOXL2RAB9APIN1DAONPC1 | |
| SCHEMBL8296766 | 0.68 | LOXL2 (0.70) | LOXL2RAB9APIN1DAONPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767645-B2 | SH2 domain binding inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080132469-A1 | 2-{(9S,10S,14R,18S)-7,16,19-Triaza-18-(carbamoylmethyl)-14-[(5-methyl indolyl)methyl]-8,17,20-trioxo-10-[4-(phosphonomethyl)phenyl]spiro[5.14]icos-11-en-9-yl}acetic acid; anticarcinogen | GOVERNMENT OF THE UNITED STATES, REPRESENTED BY THE SECRETARY, DEPARTMENT (US) | 2008-06-05 | — | — | US | disclosed |
| US-20050119163-A1 | SH2 domain binding inhibitors | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132469-A1 | 2-{(9S,10S,14R,18S)-7,16,19-Triaza-18-(carbamoylmethyl)-14-[(5-methyl indolyl)methyl]-8,17,20-trioxo-10-[4-(phosphonomethyl)phenyl]spiro[5.14]icos-11-en-9-yl}acetic acid; anticarcinogen | ICOSLG, ICOS, LCK | LOXL2 4721/4885RAB9A 1063/4885PIN1 4506/4885 |
| US-20050119163-A1 | SH2 domain binding inhibitors | GRB2, SRC, LCK | LOXL2 4291/4885RAB9A 1485/4885PIN1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.